Literature DB >> 20663350

MR Quantification of Flow in Children with Vein of Galen Malformations.

K J Poskitt1, T Marotta, G Culham, S Xiang.   

Abstract

SUMMARY: Vein of Galen vascular malformations are either Vein of Galen Aneurysmal malformations (VGAMs) or Vein of Galen Aneurysmal Dilatations (VGADs). VGAMs may be of the choroidal or mural type and are fistulas associated with the precursor of the vein of Galen. The treatment of VGAMs is aimed at controlling the size of the vascular shunt since it is believed that the shunt is responsible for venous hypertension, cardiac stress, delayed development and may be so large as to damage the brain. In VGAMs as noted by Berenstein and Lasjaunias. Absolute measures of flow may contribute to our understanding of CNS disease and permit objective measures of the success or failure of therapeutic interventions (5). MR phase contrast cine angiographic techniques can be employed to measure bulk flow in intracranial vessels. Vein of Galen vascular malformations are an ideal model to measure venous flow as the draining vein is large and angiographic evaluation is limited. Thus our goal was to develop an objective non-invasive method of measuring vascular flow in VGAMs and VGADs (6) . Herein we report our experience using this technique in a group of patients with Vein of Galen vascular malformations. We also hypothesized that the degree of shunting would correlate to the degree of cardiac stress and be an indicator of optimal timing for intervention. We believe that we have succeeded in our goal to develop an objective, non-invasive method of shunt quantification using velocity encoded MR sequences. This promises new insight into the hemodynamics, natural history and treatment response of vascular malformations.

Entities:  

Year:  2001        PMID: 20663350      PMCID: PMC3621058          DOI: 10.1177/159101990100700305

Source DB:  PubMed          Journal:  Interv Neuroradiol        ISSN: 1591-0199            Impact factor:   1.610


  9 in total

1.  Arterial and venous blood flow: noninvasive quantitation with MR imaging.

Authors:  L R Pelc; N J Pelc; S C Rayhill; L J Castro; G H Glover; R J Herfkens; D C Miller; R B Jeffrey
Journal:  Radiology       Date:  1992-12       Impact factor: 11.105

Review 2.  MR measurement of blood flow in the cardiovascular system.

Authors:  G H Mostbeck; G R Caputo; C B Higgins
Journal:  AJR Am J Roentgenol       Date:  1992-09       Impact factor: 3.959

3.  Factors influencing the accuracy and precision of velocity-encoded phase imaging.

Authors:  M H Buonocore; H Bogren
Journal:  Magn Reson Med       Date:  1992-07       Impact factor: 4.668

Review 4.  Phase contrast cine magnetic resonance imaging.

Authors:  N J Pelc; R J Herfkens; A Shimakawa; D R Enzmann
Journal:  Magn Reson Q       Date:  1991-10

5.  Verification and evaluation of internal flow and motion. True magnetic resonance imaging by the phase gradient modulation method.

Authors:  P R Moran; R A Moran; N Karstaedt
Journal:  Radiology       Date:  1985-02       Impact factor: 11.105

6.  The application of magnetization transfer to MR angiography with reduced total power.

Authors:  D L Parker; H R Buswell; K C Goodrich; A L Alexander; N Keck; J S Tsuruda
Journal:  Magn Reson Med       Date:  1995-08       Impact factor: 4.668

7.  Cine phase-contrast MR flow measurements: improved precision using an automated method of vessel detection.

Authors:  D J Burkart; J P Felmlee; C D Johnson; R L Wolf; A L Weaver; R L Ehman
Journal:  J Comput Assist Tomogr       Date:  1994 May-Jun       Impact factor: 1.826

Review 8.  Aneurysms of the vein of Galen: embryonic considerations and anatomical features relating to the pathogenesis of the malformation.

Authors:  C A Raybaud; C M Strother; J K Hald
Journal:  Neuroradiology       Date:  1989       Impact factor: 2.804

9.  Cerebral arteriovenous malformations: flow quantitation by means of two-dimensional cardiac-gated phase-contrast MR imaging.

Authors:  B A Wasserman; W Lin; R W Tarr; E M Haacke; E Müller
Journal:  Radiology       Date:  1995-03       Impact factor: 11.105

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.